LSKB’s Lead Project Set For Phase III Gastric Cancer Trial
This article was originally published in PharmAsia News
During an investor relations meeting in Seoul, South Korea’s HLB talked about recent clinical R&D progress for the lead project at its subsidiary LSK BioPharma and its developing pipeline. LSK revealed it is set to begin global Phase III trials for apatinib in gastric cancer and also aims to move on to the clinical development of a newly licensed in BTK inhibitor within 2016.
You may also be interested in...
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.